Targeted therapy with erlotinib may prolong survival of patients with cervical cancer

A new clinical study has found that erlotinib, a targeted antitumor agent, has promising potential to improve treatment for cervical cancer. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the results indicate that larger trials are warranted to determine whether the drug should become part of standard therapy for women with the disease.Nearly half a million new cases of cervical cancer are reported worldwide each year, making it the third most common cancer among females.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Cervical Cancer / HPV Vaccine Source Type: news